Gilteritinib

Contraindicated

Gilteritinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Gilteritinib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Gilteritinib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Gilteritinib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Gilteritinib Abametapir Increased exposure of CYP3A4 substrate Details Gilteritinib Sertraline Decreased effects of drugs that target the 5HT2B receptor or the sigma nonspecific receptor Details Gilteritinib Colchicine Colcrys Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Gilteritinib Cyclosporine Injection Atopica Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Cyclosporine Ophthalmic Cequa Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Digoxin Cardoxin® Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Dofetilide Tikosyn Increased OCT1 substrate exposure and increased incidence and severity of adverse reactions associated with the OCT1 substrate Details Gilteritinib Everolimus Afinitor Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Gilteritinib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Gilteritinib Apalutamide Erleada Reduced gilteritinib exposure Details Gilteritinib Avacopan Tavneos Increased CYP3A4 substrate exposure Details Gilteritinib Berotralstat Orladeyo Increased P-gp substrate exposure Details Gilteritinib Boceprevir Increased gilteritinib plasma concentrations Details Gilteritinib Carbamazepine Carbatrol Reduced gilteritinib exposure Details Gilteritinib Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Gilteritinib Clarithromycin Biaxin Increased gilteritinib plasma concentrations Details Gilteritinib Cobicistat Tybost Increased gilteritinib plasma concentrations Details Gilteritinib Conivaptan Vaprisol Increased CYP3A substrate exposure Details Gilteritinib Cyclosporine Atopica Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Gilteritinib Escitalopram Lexapro Decreased effects of drugs that target the 5HT2B receptor or the sigma nonspecific receptor Details Gilteritinib Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Gilteritinib Fexinidazole An increased CYP3A4 substrate exposure Details Gilteritinib Fluoxetine RECONCILE Decreased effects of drugs that target the 5HT2B receptor or the sigma nonspecific receptor Details Gilteritinib Fosphenytoin Cerebyx Reduced gilteritinib exposure Details Gilteritinib Idelalisib Zydelig Increased gilteritinib plasma concentrations Details Gilteritinib Indinavir Increased gilteritinib plasma concentrations Details